What: Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ:JUNO) gained as much as 30% in pre-market trading today on the news that the FDA lifted the clinical hold on its lead product candidate JCAR015, a novel form of cellular therapy known as chimeric antigen receptor T cells (or CAR-T for short). The rival CAR-T developer Kite Pharma (NASDAQ:KITE) is also benefiting from this news, with its shares up by nearly double digits in pre-market trading.
To get the study back on track, Juno requested to modify the trial protocol by excluding the chemotherapy fludarabine from the pre-conditioning regimen. As a refresher, Juno's stock plummeted last Friday after the company disclosed that the FDA placed a clinical hold on JCAR015 following two patient deaths in the therapy's ongoing mid-stage trial in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
So what: Right after the hold was made public, Juno immediately suggested that the addition of fludarabine to the trial's protocol was the main culprit in these deaths. And, apparently, the FDA is in agreement, given that the hold was lifted in only a matter of days.
Now what: Juno's stated goal is to be among the first to bring a CAR-T therapy to market -- perhaps following closely behind Kite's KTE-C19 as a possible treatment for aggressive non-Hodgkin lymphoma. Now that this clinical hold has been lifted, Juno may indeed be able to achieve this lofty goal. But the company's rather aggressive commercialization strategy is going to depend on JCAR015's ability to continue to produce unprecedented response rates in ALL without the use of fludarabine.
As CAR-T therapies in general have been plagued by safety concerns pretty much from the get-go, I'm not convinced there's a compelling reason to rush into these speculative biotech stocks right now. After all, Kite and Juno are both working on refining their CAR-T product pipelines in light of these outstanding safety issues, and it's still unclear if CAR-Ts will turn out to be viable first lines of therapy.
George Budwell has no position in any stocks mentioned. The Motley Fool recommends Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.